ARTICLE | Strategy

Guest Commentary: Paying for cures

How payers, companies can evaluate the value of new drugs

October 20, 2014 7:00 AM UTC

Advances in science are ushering in a wave of targeted drugs and biopharmaceuticals that deliver more precise and predictable outcomes to patients with fewer toxic side effects. But such products often come with higher prices. Purchasers are grappling with whether and how to cover these expensive drugs and are increasingly shifting the cost to patients who incur potentially unaffordable high out-of-pocket costs.

Avalere is proposing a decision matrix to help both payers and manufacturers evaluate the value of new drugs and define the type of financing options that will make these treatments accessible to patients...